177 related articles for article (PubMed ID: 32454195)
41. Association between laminin γ1 expression and meningioma grade, recurrence, and progression-free survival.
Ke HL; Ke RH; Li B; Wang XH; Wang YN; Wang XQ
Acta Neurochir (Wien); 2013 Jan; 155(1):165-71. PubMed ID: 23053286
[TBL] [Abstract][Full Text] [Related]
42. A study of UbcH10 expression and its association with recurrence of meningiomas.
Jiang L; Wang T; Bao Y; Qian J; Wu XJ; Hu GH; Lu YC
J Surg Oncol; 2012 Sep; 106(3):327-31. PubMed ID: 22095464
[TBL] [Abstract][Full Text] [Related]
43. DNA topoisomerase IIα and mitosin expression predict meningioma recurrence better than histopathological grade and MIB-1 after initial surgery.
Winther TL; Torp SH
PLoS One; 2017; 12(3):e0172316. PubMed ID: 28301542
[TBL] [Abstract][Full Text] [Related]
44. Skull base atypical meningioma: long term surgical outcome and prognostic factors.
Wang YC; Chuang CC; Wei KC; Hsu YH; Hsu PW; Lee ST; Wu CT; Tseng CK; Wang CC; Chen YL; Jung SM; Chen PY
Clin Neurol Neurosurg; 2015 Jan; 128():112-6. PubMed ID: 25486076
[TBL] [Abstract][Full Text] [Related]
45. Grade 3 meningioma survival and recurrence outcomes in an international multicenter cohort.
Tosefsky K; Rebchuk AD; Wang JZ; Ellenbogen Y; Drexler R; Ricklefs FL; Sauvigny T; Schüller U; Cutler CB; Lucke-Wold B; Mehkri Y; Lama S; Sutherland GR; Karsy M; Hoh BL; Westphal M; Zadeh G; Yip S; Makarenko S
J Neurosurg; 2024 Feb; 140(2):393-403. PubMed ID: 37877968
[TBL] [Abstract][Full Text] [Related]
46. Is Falcine Meningioma a Diffuse Disease of the Falx? Case Series and Analysis of a "Grade Zero" Resection.
Mooney MA; Abolfotoh M; Bi WL; Tavanaiepour D; Almefty RO; Bassiouni H; Pravdenkova S; Dunn IF; Al-Mefty O
Neurosurgery; 2020 Oct; 87(5):900-909. PubMed ID: 32294205
[TBL] [Abstract][Full Text] [Related]
47. Atypical Meningiomas: Histologic and Clinical Factors Associated With Recurrence.
Ros-Sanjuan A; Iglesias-Moroño S; Carrasco-Brenes A; Bautista-Ojeda D; Arraez-Sanchez MA
World Neurosurg; 2019 May; 125():e248-e256. PubMed ID: 30684705
[TBL] [Abstract][Full Text] [Related]
48. MIB-1 labeling indices in benign, aggressive, and malignant meningiomas: a study of 90 tumors.
Abramovich CM; Prayson RA
Hum Pathol; 1998 Dec; 29(12):1420-7. PubMed ID: 9865827
[TBL] [Abstract][Full Text] [Related]
49. Clinical and histopathological predictors of outcome in malignant meningioma.
Maier AD; Bartek J; Eriksson F; Ugleholdt H; Juhler M; Broholm H; Mathiesen TI
Neurosurg Rev; 2020 Apr; 43(2):643-653. PubMed ID: 30868425
[TBL] [Abstract][Full Text] [Related]
50. Recurrence of intracranial meningioma after surgery: analysis of influencing factors and outcome.
Bumrungrachpukdee P; Pruphetkaew N; Phukaoloun M; Pheunpathom N
J Med Assoc Thai; 2014 Apr; 97(4):399-406. PubMed ID: 24964682
[TBL] [Abstract][Full Text] [Related]
51. WHO grade 1 meningioma recurrence: Are location and Simpson grade still relevant?
Gallagher MJ; Jenkinson MD; Brodbelt AR; Mills SJ; Chavredakis E
Clin Neurol Neurosurg; 2016 Feb; 141():117-21. PubMed ID: 26780494
[TBL] [Abstract][Full Text] [Related]
52. p-CREB expression in human meningiomas: correlation with angiogenesis and recurrence risk.
Barresi V; Branca G; Caffo M; Tuccari G
J Neurooncol; 2015 Mar; 122(1):87-95. PubMed ID: 25563814
[TBL] [Abstract][Full Text] [Related]
53. Relationship between malignant subtypes of meningioma and clinical outcome.
Ko KW; Nam DH; Kong DS; Lee JI; Park K; Kim JH
J Clin Neurosci; 2007 Aug; 14(8):747-53. PubMed ID: 17499508
[TBL] [Abstract][Full Text] [Related]
54. Prognostic Factors, Survival, and Treatment for Intracranial World Health Organization Grade II Chordoid Meningiomas and Clear-Cell Meningiomas.
Zhang GJ; Zhang YS; Zhang GB; Yan XJ; Li CB; Zhang LW; Li D; Wu Z; Zhang JT
World Neurosurg; 2018 Sep; 117():e57-e66. PubMed ID: 29859361
[TBL] [Abstract][Full Text] [Related]
55. Phosphohistone-H3 Proliferation Index Is Superior to Mitotic Index and MIB-1 Expression as a Predictor of Recurrence in Human Meningiomas.
Winther TL; Arnli MB; Salvesen Ø; Torp SH
Am J Clin Pathol; 2016 Oct; 146(4):510-20. PubMed ID: 27686177
[TBL] [Abstract][Full Text] [Related]
56. Significance of COX-2 and VEGF expression in histopathologic grading and invasiveness of meningiomas.
Lee SH; Lee YS; Hong YG; Kang CS
APMIS; 2014 Jan; 122(1):16-24. PubMed ID: 23756256
[TBL] [Abstract][Full Text] [Related]
57. Long-term surgical outcomes of spinal meningiomas.
Nakamura M; Tsuji O; Fujiyoshi K; Hosogane N; Watanabe K; Tsuji T; Ishii K; Toyama Y; Chiba K; Matsumoto M
Spine (Phila Pa 1976); 2012 May; 37(10):E617-23. PubMed ID: 22146282
[TBL] [Abstract][Full Text] [Related]
58. Prognostic factors for survival in patients with high-grade meningioma and recurrence-risk stratification for application of radiotherapy.
Yamaguchi S; Terasaka S; Kobayashi H; Asaoka K; Motegi H; Nishihara H; Kanno H; Onimaru R; Ito YM; Shirato H; Houkin K
PLoS One; 2014; 9(5):e97108. PubMed ID: 24820480
[TBL] [Abstract][Full Text] [Related]
59. Surgical Treatment and Predictive Factors for Atypical Meningiomas: A Multicentric Experience.
Dobran M; Marini A; Splavski B; Rotim K; Liverotti V; Nasi D; Iacoangeli M
World Neurosurg; 2020 Dec; 144():e1-e8. PubMed ID: 32311549
[TBL] [Abstract][Full Text] [Related]
60. Immunohistochemical study of anaplastic meningioma with special reference to the phenotypic change of intermediate filament protein.
Ikeda H; Yoshimoto T
Ann Diagn Pathol; 2003 Aug; 7(4):214-22. PubMed ID: 12913843
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
